GOVX

GeoVax Labs, Inc.

Price Chart

Latest Quote

$1.29

-0.03 (-2.27%)

Current Price

Previous Close	$1.32
Open	$1.26
Day High	$1.34
Day Low	$1.26
Volume	203,798

Fetched: 2026-06-24T09:07:07

Stock Information

Shares Outstanding	5.21M
Total Debt	$395K
Cash Equivalents	$1.27M
Revenue	$852K
Net Income	$-21.37M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$6.72M
EPS (TTM)	$-13.82
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$3.60M
Sales	$852K
Income	$-21.37M
Book/sh	$0.17
Cash/sh	$0.24
Employees	19

Financial Ratios

Quick Ratio	0.56
Current Ratio	1.06
Debt/Eq	79.91

Returns & Margins

ROA	-194.59%
ROE	-509.28%
Operating Margin	-2523.43%

Ownership

Insider Ownership	6.82%
Institutional Ownership	18.28%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.50
P/S	7.89
P/B	7.37

Analyst Data

Recommendation	none
Target Price	$10.00

Technical Indicators

SMA20	$1.70
SMA50	$1.58
SMA200	$6.18
RSI	17.07
ATR	0.2096

Shares Float	3.15M
Short Float	11.22%
Short Ratio	0.04
Volatility	3.63
Rel Volume	0.15

Performance History

Week	+9.32%
Month	-53.09%
Quarter	-14.00%
6 Months	-78.50%
YTD	-75.07%
Year	-94.53%
3 Years	-99.46%
5 Years	-99.94%
10 Years	-99.88%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$1.29	204,700
2026-06-22	$1.32	539,700
2026-06-18	$1.34	664,800
2026-06-17	$1.18	397,100
2026-06-16	$1.17	687,900
2026-06-15	$1.18	1,060,700
2026-06-12	$1.22	3,591,700
2026-06-11	$1.18	373,400
2026-06-10	$1.20	520,000
2026-06-09	$1.28	562,100
2026-06-08	$1.34	777,500
2026-06-05	$1.65	652,100
2026-06-04	$1.79	2,032,500
2026-06-03	$2.03	641,300
2026-06-02	$2.10	670,800
2026-06-01	$2.21	2,034,100
2026-05-29	$2.06	1,112,100
2026-05-28	$2.40	1,894,800
2026-05-27	$2.67	2,772,500
2026-05-26	$3.49	5,622,500

About GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

📰 Latest News

GeoVax Labs (GOVX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks • 2026-06-12T13:55:02Z

Is Co-Diagnostics National Security’s Next Diagnostic Pick?

MarketBeat • 2026-05-28T15:00:00Z

Why Is GOVX Stock Falling Today?

Stocktwits • 2026-05-26T15:45:19Z

How The GeoVax Labs (GOVX) Story Is Shifting With Vaccine Progress And Funding Risks

Simply Wall St. • 2026-05-26T11:08:30Z

All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy

Zacks • 2026-05-15T16:00:02Z

How The GeoVax Labs (GOVX) Story Is Shifting After The Rating Downgrade And Valuation Reset

Simply Wall St. • 2026-04-14T13:05:52Z

Why The GeoVax Labs (GOVX) Story Is Shifting As Valuation Holds And Risks Rise

Simply Wall St. • 2026-03-31T07:05:39Z

How The Story On GeoVax Labs (GOVX) Is Shifting Toward Execution Risk And Funding Constraints

Simply Wall St. • 2026-03-11T17:09:41Z

Siga Technologies Q4 Earnings Call Highlights

MarketBeat • 2026-03-10T22:41:40Z

Shopify, eBay upgraded: Wall Street's top analyst calls

The Fly • 2026-02-19T14:40:27Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$2,489,145	$3,954,576	$0	$81,526
Operating Revenue	$2,489,145	$3,954,576	$0	$81,526
Expenses
Interest Expense	$0	$21,375	$0	$0
Total Expenses	$24,128,192	$29,098,856	$26,742,939	$14,110,090
Net Non Operating Interest Income Expense	$174,276	$151,984	$776,177	$7,439
Interest Expense Non Operating	$0	$21,375	$0	$0
Operating Expense	$24,128,192	$29,098,856	$26,742,939	$14,110,090
General And Administrative Expense	$6,006,673	$5,385,254	$6,022,173	$4,986,611
Other Income Expense	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Net Interest Income	$174,276	$151,984	$776,177	$7,439
Interest Income	$174,276	$173,359	$776,177	$7,439
Normalized Income	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Net Income From Continuing And Discontinued Operation	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Total Operating Income As Reported	$-21,639,047	$-25,144,280	$-26,742,939	$-14,028,564
Net Income Common Stockholders	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Net Income	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Net Income Including Noncontrolling Interests	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Net Income Continuous Operations	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Pretax Income	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Interest Income Non Operating	$174,276	$173,359	$776,177	$7,439
Operating Income	$-21,639,047	$-25,144,280	$-26,742,939	$-14,028,564
Special Income Charges	-	-	-	$0
Per Share
Diluted EPS	$-22.40	$-120.46	$-357.25	$-311.25
Basic EPS	$-22.40	$-120.46	$-357.25	$-311.25
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-21,396,015	$-24,875,553	$-25,892,593	$-13,972,280
Reconciled Depreciation	$68,756	$95,368	$74,169	$56,284
EBITDA (Bullshit earnings)	$-21,396,015	$-24,875,553	$-25,892,593	$-13,972,280
EBIT	$-21,464,771	$-24,970,921	$-25,966,762	$-14,028,564
Diluted Average Shares	$958,443	$207,482	$72,691	$45,261
Basic Average Shares	$958,443	$207,482	$72,691	$45,261
Diluted NI Availto Com Stockholders	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Research And Development	$18,121,519	$23,713,602	$20,720,766	$9,123,479
Selling General And Administration	$6,006,673	$5,385,254	$6,022,173	$4,986,611
Other Gand A	$6,006,673	$5,385,254	$6,022,173	$4,986,611
Total Unusual Items	-	-	-	$0
Total Unusual Items Excluding Goodwill	-	-	-	$0
Other Special Charges	-	-	-	-

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$3,775,132	$4,988,535	$5,693,338	$26,600,034
Total Assets	$6,341,868	$8,155,867	$9,283,219	$31,347,928
Total Non Current Assets	$1,027,217	$220,984	$1,397,477	$2,409,198
Non Current Prepaid Assets	$36,947	$11,010	$1,117,788	$2,174,286
Goodwill And Other Intangible Assets	$50,000	$60,000	$70,000	$80,000
Other Intangible Assets	$50,000	$60,000	$70,000	$80,000
Current Assets	$5,314,651	$7,934,883	$7,885,742	$28,938,730
Other Current Assets	$66,843	$10,000	-	-
Prepaid Assets	$2,162,067	$1,758,533	$1,433,153	$1,325,998
Receivables	$0	$659,409	$0	$0
Cash Cash Equivalents And Short Term Investments	$3,085,741	$5,506,941	$6,452,589	$27,612,732
Cash And Cash Equivalents	$3,085,741	$5,506,941	$6,452,589	$27,612,732
Other Receivables	-	$659,409	-	-
Other Non Current Assets	-	-	$1,187,788	$2,174,286
Debt
Total Debt	$843,170	$0	-	-
Long Term Debt And Capital Lease Obligation	$580,035	$0	-	-
Current Debt And Capital Lease Obligation	$263,135	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$2,516,736	$3,107,332	$3,519,881	$4,747,894
Total Non Current Liabilities Net Minority Interest	$580,035	$0	$0	$0
Current Liabilities	$1,936,701	$3,107,332	$3,519,881	$4,747,894
Payables And Accrued Expenses	$1,673,566	$3,107,332	$3,519,881	$4,747,894
Payables	$790,750	$1,849,760	$2,802,950	$1,747,682
Accounts Payable	$790,750	$1,849,760	$2,802,950	$1,747,682
Other Non Current Liabilities	-	-	-	-
Equity
Common Stock Equity	$3,825,132	$5,048,535	$5,763,338	$26,600,034
Total Equity Gross Minority Interest	$3,825,132	$5,048,535	$5,763,338	$26,600,034
Stockholders Equity	$3,825,132	$5,048,535	$5,763,338	$26,600,034
Retained Earnings	$-150,820,852	$-129,356,081	$-104,363,785	$-78,397,023
Other
Ordinary Shares Number	$1,732,147	$421,475	$79,086	$70,226
Share Issued	$1,732,147	$421,475	$79,086	$70,226
Tangible Book Value	$3,775,132	$4,988,535	$5,693,338	$26,600,034
Invested Capital	$3,825,132	$5,048,535	$5,763,338	$26,600,034
Working Capital	$3,377,950	$4,827,551	$4,365,861	$24,190,836
Capital Lease Obligations	$843,170	$0	-	-
Total Capitalization	$3,825,132	$5,048,535	$5,763,338	$26,600,034
Additional Paid In Capital	$154,644,252	$134,404,195	$110,125,146	$104,995,301
Capital Stock	$1,732	$421	$1,977	$1,756
Common Stock	$1,732	$421	$1,977	$1,756
Long Term Capital Lease Obligation	$580,035	$0	-	-
Current Capital Lease Obligation	$263,135	$0	-	-
Current Accrued Expenses	$882,816	$1,257,572	$716,931	$3,000,212
Net PPE	$940,270	$149,974	$209,689	$234,912
Accumulated Depreciation	$-403,607	$-761,042	$-680,674	$-606,505
Gross PPE	$1,343,877	$911,016	$890,363	$841,417
Leases	$0	$115,605	$115,605	$115,605
Machinery Furniture Equipment	$512,437	$795,411	$774,758	$725,812
Buildings And Improvements	$831,440	$0	-	-
Properties	$0	$0	$0	$0
Treasury Shares Number	-	-	$0	-
Preferred Stock	-	-	-	-
Non Current Accrued Expenses	-	-	-	-

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-21,501,581	$-24,696,164	$-25,222,585	$-19,164,466
Operating Activities
Operating Cash Flow	$-21,473,969	$-24,675,511	$-25,173,639	$-19,030,208
Cash Flow From Continuing Operating Activities	$-21,473,969	$-24,675,511	$-25,173,639	$-19,030,208
Operating Gains Losses	-	-	-	-
Investing Activities
Capital Expenditure	$-27,612	$-20,653	$-48,946	$-134,258
Investing Cash Flow	$-27,612	$-20,653	$-48,946	$-134,258
Cash Flow From Continuing Investing Activities	$-27,612	$-20,653	$-48,946	$-134,258
Financing Activities
Issuance Of Capital Stock	$18,924,172	$21,398,383	$0	$27,727,194
Financing Cash Flow	$19,080,381	$23,750,516	$4,062,442	$35,353,328
Cash Flow From Continuing Financing Activities	$19,080,381	$23,750,516	$4,062,442	$35,353,328
Net Common Stock Issuance	$18,924,172	$21,398,383	$0	$27,727,194
Common Stock Issuance	$18,924,172	$21,398,383	$0	$27,727,194
Repurchase Of Capital Stock	-	-	-	$0
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	-
Other
Repayment Of Debt	$0	$-150,000	$0	$0
Issuance Of Debt	$0	$135,000	$0	-
End Cash Position	$3,085,741	$5,506,941	$6,452,589	$27,612,732
Beginning Cash Position	$5,506,941	$6,452,589	$27,612,732	$11,423,870
Changes In Cash	$-2,421,200	$-945,648	$-21,160,143	$16,188,862
Proceeds From Stock Option Exercised	$156,209	$2,367,133	$4,062,442	$7,626,134
Net Issuance Payments Of Debt	$0	$-15,000	$0	$0
Net Short Term Debt Issuance	$0	$-15,000	$0	$0
Short Term Debt Payments	$0	$-150,000	$0	$0
Short Term Debt Issuance	$0	$135,000	$0	-
Net PPE Purchase And Sale	$-27,612	$-20,653	$-48,946	$-134,258
Purchase Of PPE	$-27,612	$-20,653	$-48,946	$-134,258
Change In Working Capital	$-1,193,108	$-307,227	$-356,003	$-5,967,441
Change In Other Current Assets	$27,623	$1,116,778	$986,498	$-2,163,276
Change In Payables And Accrued Expense	$-1,465,596	$-412,549	$-1,228,013	$-2,687,466
Change In Prepaid Assets	$-414,544	$-352,047	$-114,488	$-1,165,705
Change In Receivables	$659,409	$-659,409	$0	$49,006
Stock Based Compensation	$1,115,154	$528,644	$1,074,957	$902,074
Depreciation Amortization Depletion	$68,756	$95,368	$74,169	$56,284
Depreciation And Amortization	$68,756	$95,368	$74,169	$56,284
Depreciation	$68,756	-	$74,169	$56,284
Net Income From Continuing Operations	$-21,464,771	$-24,992,296	$-25,966,762	$-14,021,125
Preferred Stock Payments	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$0
Long Term Debt Payments	-	-	-	$0
Change In Other Working Capital	-	-	-	$-2,163,276
Long Term Debt Issuance	-	-	-	-
Gain Loss On Investment Securities	-	-	-	-

Fetched: 2026-06-22